Eli Lilly says 700,000 seniors started GLP-1 treatment after Medicare opened obesity-drug coverage, with its medicines serving seven in 10 new patients.
CEO Dave Ricks told CNBC that the figures cover the period since Medicare launched the coverage in July. He called the early response “very encouraging.”
The rollout matters because Medicare covers about 66 million elderly and disabled Americans. Eligible beneficiaries can obtain weight-loss drugs through a temporary program called Bridge, which sets a $50 monthly co-pay.
Ricks said Lilly was “capturing about seven out of 10 of those new patients.” He added that “a lot are still on Zepbound.”
The program includes Lilly’s Zepbound and Foundayo, along with Novo’s Wegovy products. That gives Medicare patients access to injectable and oral GLP-1 options from the two rival drugmakers.
Ricks said doctors continue to steer patients with the greatest needs toward Zepbound. He cited both body weight and related complications as factors in those treatment decisions.
“I think we still see physicians focusing on those with the most body weight and the most complications. That's where Zepbound plays a big role,” Ricks said.
Foundayo appears to be drawing a different group. Ricks said one-third of new patients taking oral GLP-1 medicines were using Lilly’s pill, which launched in April.
Some Foundayo patients, he said, “maybe just need to lose 25 to 30 pounds.” That distinction could help explain why Zepbound remains prominent among patients facing more serious complications.
Ricks credited the Centers for Medicare and Medicaid Services with educating doctors and working with drugmakers and insurers. He said the agency “did a nice job rolling this out.”
He also said the expansion of the broader GLP-1 market “is what we had hoped.” For Lilly, the reported result is substantial: 70% of 700,000 new senior patients amounts to a commanding position within this early group.
But the public account did not identify the data behind either the 700,000 total or Lilly’s 70% figure. It also did not specify the Bridge program’s full eligibility rules or the exact July launch date.
Those details matter when a temporary federal program reaches hundreds of thousands of people. Early adoption may please drugmakers, but public programs still owe beneficiaries and taxpayers a clear accounting.
Access and accountability should advance together. A federal health program does its job best when patients can use it and the public can plainly measure it.